J. Borenstein previously was employed by Amgen. D. Kendler has received grant or research support from Amgen, Merck, Eli Lilly, Novartis, Procter & Gamble, GlaxoSmithKline, Pfizer, Roche Biosante, and
Wyeth and has served as an advisor for Amgen, Merck, Eli Lilly, Novartis, Wyeth, Nycomed, Procter & Gamble, and Pfizer. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, Ganetespib manufacturer provided the original author(s) and source are credited. Appendix The Denosumab Adherence Preference Satisfaction (DAPS) study investigators were as follows, listed alphabetically by country: USA—Bruce Akright, Kurt Datz, Ara Dikranian,
Elyse Erlich, Stephen Fehnel, Catherine Gerrish, John Joseph, Robert Lang, Leroy Leeds, Michael Lillestol, Dennis Linden, Michael McClung, Jefferey Michelson, Alfred Moffett, Constantine Saadeh, Gerald Shockey, Joseph Soufer, Raul Tamayo, and John Williams; Canada—Jonathan Adachi, Stephanie Kaiser, David Kendler, Jean-Pierre Raynauld, and Jerieta Waltin-James. Electronic supplementary material Below is the link to the electronic supplementary material. Image Online resource 1 (GIF 53 kb) High-resolution image (EPS 343 kb) Online resource 2 (PDF 37 kb) References 1. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis
increases fracture risk: systematic review Palbociclib supplier and meta-analysis. Osteoporos Int 21:1943–1951PubMedCrossRef 2. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501PubMedCrossRef 3. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. mafosfamide Mayo Clin Proc 81:1013–1022PubMedCrossRef 4. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202–210PubMedCrossRef 5. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef 6. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef 7. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740PubMed 8.